Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
Recruiting · NCT05577819 · Interventional (participants receive a specific treatment) · Lead sponsor: Massachusetts General Hospital
View the official record on ClinicalTrials.gov →Interventions studied
99mTc-pyrophosphate Scintigraphy
What this trial is about
Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF) or diastolic heart failure. In this single center diagnostic study, we will evaluate for ATTR in patients with HFpEF in order to to determine how frequently this occurs and how we can predict which heart failure patients may have TTR amyloidosis. Our goal is to identify amyloidosis in heart failure patients earlier so that they can start treatment.
Who can take part
Age range
65 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patients with a confirmed diagnosis of HFpEF.
- Age ≥65 years old
Exclusion criteria
- End stage chronic kidney disease on dialysis (CKD stage 5 as defined as eGFR \<15mL/min)
- no history of HFrEF (LVEF\<40%) with the exception of low LVEF in the setting of acute decompensation, AF RVR, ACS/MI, etc
- Negative 99mTc-pyrophosphate scan within a year
- Unable to lie down for 15 minutes for the 99mTc-pyrophosphate scan
- Known diagnosis of amyloidosis
- Severe valvular heart disease that is uncorrected (moderate to severe is considered exclusionary)
Where it is running
1 location listed across 1 US state.
- Massachusetts General Hospital - Boston, Massachusetts, United States